Bausch Health Companies Inc. Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax
Bausch Health Companies Inc. (BHC) reported Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax of -$1.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax · last filed 2026-02-19
- Bausch Health Companies Inc. other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax for fiscal 2025 was -$1.00M.
- Bausch Health Companies Inc. other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax for fiscal 2024 was $0.00.
- Bausch Health Companies Inc. other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax for fiscal 2023 was -$1.00M.
- Bausch Health Companies Inc. other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax for fiscal 2022 was -$3.00M, a 400.00% decline from fiscal 2021.
| Period end | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax 12 month |
|---|---|
| 2025-12-31 | -$1.00M 10-K · filed 2026-02-19 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-19 |
| 2023-12-31 | -$1.00M 10-K · filed 2026-02-19 |
| 2022-12-31 | -$3.00M 10-K · filed 2025-02-20 |
| 2021-12-31 | $1.00M 10-K · filed 2024-02-22 |
| 2020-12-31 | $2.00M 10-K · filed 2023-02-23 |
| 2019-12-31 | -$2.00M 8-K · filed 2022-05-11 |
| 2018-12-31 | $3.00M 8-K · filed 2021-05-04 |
| 2017-12-31 | -$4.00M 10-K · filed 2020-02-19 |
| 2016-12-31 | $4.00M 10-K · filed 2019-02-20 |
| 2015-12-31 | -$3.00M 8-K · filed 2018-08-10 |
| 2014-12-31 | $28.00M 10-K · filed 2017-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |